Видео с ютуба Egfr Nsclc

Понимание лечения НМРЛ при наличии мутации EGFR

Понимание лечения НМРЛ при наличии мутации EGFR
EGFR Resisters Welcome Video: How We Can Help with EGFR+ NSCLC

EGFR Resisters Welcome Video: How We Can Help with EGFR+ NSCLC
Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC

Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum
Case #2: Treating a Patient with Stage IV NSCLC with EGFR - 2025 Case Based Panel Discussions

Case #2: Treating a Patient with Stage IV NSCLC with EGFR - 2025 Case Based Panel Discussions
EGFR-Mutant Lung Cancer & Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum

EGFR-Mutant Lung Cancer & Treatment Options | 2023 Living with EGFR-Mutant Lung Cancer Patient Forum
Что такое мутация EGFR при раке легких?

Что такое мутация EGFR при раке легких?
Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC

Finding the Optimal Treatment for EGFR-mutated Metastatic NSCLC
FLAURA2 outcomes by EGFR mutation subtype in advanced NSCLC

FLAURA2 outcomes by EGFR mutation subtype in advanced NSCLC
Сложные случаи метастатического немелкоклеточного рака легких с мутацией EGFR с доктором Эриком С...

Сложные случаи метастатического немелкоклеточного рака легких с мутацией EGFR с доктором Эриком С...
NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over Chemotherapy

NSCLC With EGFR Exon 20 Shows Benefit With Mobocertinib Over Chemotherapy
Dr. Piotrowska on Treatment for EGFR-Mutant NSCLC

Dr. Piotrowska on Treatment for EGFR-Mutant NSCLC
Treating Uncommon EGFR NSCLC Mutations with Osimertinib

Treating Uncommon EGFR NSCLC Mutations with Osimertinib
The challenge of treatment resistance in patients with advanced EGFR-mutated NSCLC

The challenge of treatment resistance in patients with advanced EGFR-mutated NSCLC
Sunvozertinib for NSCLC with EGFR Exon 20 - Lung Cancer OncInsights 2025-26

Sunvozertinib for NSCLC with EGFR Exon 20 - Lung Cancer OncInsights 2025-26
Multimodal Management of Early-Stage NSCLC: EGFR-Targeted Therapy in Perioperative Settings

Multimodal Management of Early-Stage NSCLC: EGFR-Targeted Therapy in Perioperative Settings
Therapy for EGFR Classical Mutation in NSCLC - 2025 Targeted Therapies in Lung Cancer Patient Forum

Therapy for EGFR Classical Mutation in NSCLC - 2025 Targeted Therapies in Lung Cancer Patient Forum
Safety of osimertinib plus tegavivint in first-line EGFR-mutant NSCLC

Safety of osimertinib plus tegavivint in first-line EGFR-mutant NSCLC
Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
LAURA: osimertinib and chemoradiotherapy in stage III EGFR-m NSCLC

LAURA: osimertinib and chemoradiotherapy in stage III EGFR-m NSCLC